Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;599(18):2582-2597.
doi: 10.1002/1873-3468.70091. Epub 2025 Jun 12.

Genomic modifiers of neurological resilience in a Niemann-Pick C family

Macarena Las Heras  1 , Benjamín Szenfeld  1 , Valeria Olguín  1 , Juan Carlos Rubilar  1 , Juan Francisco Calderón  1 , Yanireth Jimenez  1 , Silvana Zanlungo  2 , Emanuele Buratti  3 , Andrea Dardis  4 , Francisco A Cubillos  5   6 , Andrés D Klein  1
Affiliations

Genomic modifiers of neurological resilience in a Niemann-Pick C family

Macarena Las Heras et al. FEBS Lett. 2025 Sep.

Abstract

Niemann-Pick type C (NPC) disease, caused by NPC1 or NPC2 variants, disrupts cholesterol and glycolipid trafficking, leading to diverse clinical manifestations. To understand the genetic basis of neurological resilience, we analyzed an NPC family with variable phenotypes, identifying loss-of-function variants in CCDC115, SLC4A5, DEPDC5, ETFDH, SNRNP200, and DOCK1 that co-segregated with milder neurological involvement. Using yeast models, we successfully predicted NPC-like severity based on orthologous gene variants. RNA-seq revealed a positive correlation between mitochondrial transcripts and cellular fitness. Modeling NPC in yeast lacking the SLC4A5 ortholog, bor1, enhanced cellular fitness, improved mitochondrial function, and reduced sterol accumulation. Our findings identify potential modifiers and biomarkers of NPC severity, highlighting mitochondrial pathways and SLC4A5 as a therapeutic target. Impact statement Niemann-Pick type C (NPC) disease is a progressive neurovisceral lysosomal storage disorder. Here, we identified genomic modifiers of neurological resilience in an NPC family, with SLC4A5 emerging as a key biomarker and therapeutic target. Additionally, our study highlighted mitochondrial transcripts and metabolites as potential biomarkers of severity.

Keywords: SLC4A5; bor1; Niemann‐Pick Type C; modifier genes; neurodegeneration; precision medicine.

PubMed Disclaimer

References

    1. Platt FM (2014) Sphingolipid lysosomal storage disorders. Nature 510, 68–75.
    1. Klein AD, Alvarez A and Zanlungo S (2014) The unique case of the Niemann‐pick type C cholesterol storage disorder. Pediatr Endocrinol Rev 12(Suppl 1), 166–175.
    1. Bolton SC, Soran V, Marfa MP, Imrie J, Gissen P, Jahnova H, Sharma R, Jones S, Santra S, Crushell E et al. (2022) Clinical disease characteristics of patients with Niemann‐pick disease type C: findings from the international Niemann‐pick disease registry (INPDR). Orphanet J Rare Dis 17, 51.
    1. Las Heras M, Szenfeld B, Ballout RA, Buratti E, Zanlungo S, Dardis A and Klein AD (2023) Understanding the phenotypic variability in Niemann‐pick disease type C (NPC): a need for precision medicine. NPJ Genom Med 8, 21.
    1. Wassif CA, Cross JL, Iben J, Sanchez‐Pulido L, Cougnoux A, Platt FM, Ory DS, Ponting CP, Bailey‐Wilson JE, Biesecker LG et al. (2016) High incidence of unrecognized visceral/neurological late‐onset Niemann‐pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genet Med 18, 41–48.

LinkOut - more resources